A vision for the world

Article

Helping others to help themselves

Back in 2002,Max Reindl, founder and chief executive officer of Wavelight AG and his colleague, Susanne Grethlein, vice president marketing and investor relations founded the sponsoring association Vision for the World (VFTW). Its aim was, and still is, to give something back to the ophthalmic community from businesses that serve it.

"At ECWA I learnt basic history and examination of ophthalmic patients. I also learnt from weekly hospital presentations reviewing journals. I was taught simple cataract surgery and other minor surgeries like chalazion I&C, pterygyium excision and lid rotation. I personally completed 21 cataract surgeries before leaving for my Community Eye Health posting at National Eye Centre Kaduna and am doing fine."

Phase three, which currently under preparation, will see the start-up team getting initial experience using the phacoemulsifaction unit themselves. VFTW will then send out a partner doctor to provide refresher courses and regular training sessions. The aim is for this to be at the end of this year or the beginning of 2011.

The fourth and final phase will be when the start-up team have enough experience and can begin training their colleagues and incoming students in the future.

"Incentives must be created for the outstandingly trained doctors to apply their acquired professional knowledge in their home country for the benefit of the patients", says Max Reindl.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.